Protagenic Therapeutic -CW25PTIXWPreferred / convertible
13F holders, Q4 2025 (December 31)3holders −1
0new positions
1sold out
$0.03avg. 13F price*
At the end of Q4 2025, 3 institutions reported holding Protagenic Therapeutic -CW25 (PTIXW) in their 13F filings, down 1 from Q3 2025. 0 opened new positions and 1 sold out. The largest holders were Susquehanna International Group, LLP ($3K), Clear Street Group Inc. ($2K) and Two Sigma Securities, LLC ($371).
- Company
- Protagenic Therapeutic -CW25
- CUSIP
- 74365N111
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $2 |
All 13F filers, Q3 2025 → Q4 2025: 3,181 shares bought and 100 shares sold, net +3,081 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Susquehanna International Group, LLP | — | No change | 87,596 | $3K |
| Clear Street Group Inc. | — | No change | 100,000 | $2K |
| Two Sigma Securities, LLC | — | Add +25.8% | 15,533 | $371 |
"% of holder's portfolio" is PTIXW's weight in each manager's 13F, not the share of Protagenic Therapeutic -CW25 the manager owns.